

Study evaluating a new drug to treat participants with Demodex blepharitis (inflammation of the eyelids)

Submission date 18/02/2021	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 11/03/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 11/03/2021	Condition category Eye Diseases	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

The purpose of this study is to evaluate the safety and efficacy of an eyedrop treatment for a condition known as blepharitis, which causes inflammation of the eye and dry eyes, due to infestation with the Demodex mite, which lives in the eyelashes.

Who can participate?

Adult participants with blepharitis due to Demodex infestation.

What does the study involve?

Participants will be allocated to one of two groups, with an equal chance of being in either group (like tossing a coin). Participants and researchers will not have a choice in the treatment given and participants will not know which treatment they have received during the study period. The first group of participants will receive the study drug TP-03 eyedrops and the second of participants will receive eyedrops that appear identical but do not contain active ingredients. Participants will be asked to apply the treatment they have received to each eye, twice a day, for 28 days.

What are the possible benefits and risks of participating?

Participants who receive the study drug may experience an improvement in their symptoms of eye inflammation. Participants who do not receive the study drug may not receive any direct benefit.

Potential risks for participation in this study include eye irritation (redness and/or inflammation) due to either the study drug or the inactive treatment.

Where is the study run from?

Asociacion para Evitar la Ceguera (APEC) Departamento de Investigacion (Mexico)

When is the study starting and how long is it expected to run for?

From March 2019 to August 2019

Who is funding the study?
Tarsus Pharmaceuticals (USA)

Who is the main contact?
Roberto Gonzalez Salinas, dr.gonzalezsalinas@gmail.com

Contact information

Type(s)
Scientific

Contact name
Dr Roberto Gonzalez Salinas

ORCID ID
<https://orcid.org/0000-0001-6654-5191>

Contact details
Vicente Garcia Torres 46
Colonia Barrio San Lucas
Coyoacan
Ciudad de Mexico
Mexico
04030
+52 442 219 9424
dr.gonzalezsalinas@gmail.com

Additional identifiers

Protocol serial number
TRS-004

Study information

Scientific Title
Randomized, vehicle controlled, double-blind, parallel trial to evaluate the safety and efficacy of TP- 03 for the treatment of blepharitis due to Demodex infestation (Jupiter)

Acronym
Jupiter

Study objectives
Treatment with TP-03 will result in a significant decrease from baseline in Demodex density (mites/lash) at day 28 compared to the vehicle control. Any ocular irritation experienced will be mild and similar to the vehicle control in frequency and severity.

Ethics approval required
Old ethics approval format

Ethics approval(s)

Approved 05/03/2019, Ethics and Research Committee, Asociacion para Evitar la Ceguera en Mexico I.A P. (Association to Prevent Blindness in Mexico I.A P., Vicente Garcia Torres 46, Colonia Barrio San Lucas Coyoacan, Ciudad de Mexico 04030; +52 10 84 14 00; no email address provided), ref: none provided

Study design

Prospective double-masked single-centre randomized parallel vehicle-controlled study

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Eyelid inflammation due to a parasitic (Demodex) infestation

Interventions

This study is intended to evaluate the safety and efficacy of TP-03, ophthalmic solution, 0.25% compared to vehicle control for the treatment of blepharitis due to Demodex infestation.

Participants will be randomized 1:1 in the active and control arms and will use the study drug twice a day for 28 days. A computer-generated block randomization schedule will be used to label the study drug and bottles will be assigned to participants on a consecutive basis.

Participation in the study will last for up to 90 days post-initiation of treatment.

Intervention Type

Drug

Phase

Phase II

Drug/device/biological/vaccine name(s)

TP-03 (topical ophthalmic preparation of lotilaner)

Primary outcome(s)

Change in Demodex density calculated as the number of mites per lash measured using lash epilation and mite counting via microscope at baseline and 28 days

Key secondary outcome(s)

Change in collarette grading measured using slit lamp biomicroscopy at baseline, 14, and 28 days

Completion date

19/08/2019

Eligibility

Key inclusion criteria

1. Willing to sign the informed consent and deemed capable of complying with the requirements of the study protocol
2. Participants must meet all of the following criteria in at least one eye:
 - 2.1. More than 10 collarettes present on the upper lid
 - 2.2. Mild to severe lid margin erythema
 - 2.3. Average Demodex density of 1.5 or more mites per lash
3. Aged ≥ 18 years

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Lower age limit

18 years

Sex

All

Total final enrolment

60

Key exclusion criteria

1. Systemic or topical antibacterial, antiparasitic or anti-inflammatory steroid treatment within the last 14 days
2. Topical tea tree oil or hypochlorous acid treatment of the ophthalmic area within the last 14 days
3. Use of lid hygiene products (eyelid scrubs) in the last 14 days or unwilling to forego the use of lid hygiene products during the study

Date of first enrolment

07/03/2019

Date of final enrolment

25/04/2019

Locations**Countries of recruitment**

Mexico

Study participating centre

Asociacion para Evitar la Ceguera (APEC) Departamento de Investigacion

Vicente Garcia Torres 46

Colonia Barrio San Lucas

Coyoacan
Ciudad de Mexico
Mexico
04030

Sponsor information

Organisation

Roberto Gonzalez Salinas, MD

Funder(s)

Funder type

Industry

Funder Name

Tarsus Pharmaceuticals

Results and Publications

Individual participant data (IPD) sharing plan

There is no plan to share participant-level data as the investigational product data has not yet been submitted to a regulatory authority.

IPD sharing plan summary

Not expected to be made available